JPMorgan Chase & Co. Increases Stake in Medpace Holdings, Inc. $MEDP

JPMorgan Chase & Co. boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 79.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 265,270 shares of the company’s stock after purchasing an additional 117,301 shares during the quarter. JPMorgan Chase & Co.’s holdings in Medpace were worth $83,258,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Willis Investment Counsel boosted its holdings in shares of Medpace by 56.1% in the 2nd quarter. Willis Investment Counsel now owns 12,250 shares of the company’s stock valued at $3,845,000 after purchasing an additional 4,402 shares during the last quarter. Handelsbanken Fonder AB raised its position in shares of Medpace by 6.5% in the 2nd quarter. Handelsbanken Fonder AB now owns 6,600 shares of the company’s stock worth $2,071,000 after buying an additional 400 shares during the period. Westfield Capital Management Co. LP acquired a new position in Medpace in the second quarter valued at $221,000. Ensign Peak Advisors Inc grew its position in Medpace by 24.9% during the second quarter. Ensign Peak Advisors Inc now owns 41,723 shares of the company’s stock valued at $13,095,000 after acquiring an additional 8,318 shares during the period. Finally, Empirical Finance LLC increased its stake in Medpace by 72.4% during the second quarter. Empirical Finance LLC now owns 6,974 shares of the company’s stock worth $2,189,000 after acquiring an additional 2,928 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 15,230 shares of the stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $598.85, for a total transaction of $9,120,485.50. Following the transaction, the general counsel owned 13,343 shares of the company’s stock, valued at approximately $7,990,455.55. This trade represents a 53.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This trade represents a 7.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 317,597 shares of company stock valued at $189,967,248. 20.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MEDP. Barclays lifted their price objective on Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a research note on Friday, October 24th. Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Cowen reiterated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Finally, Zacks Research raised shares of Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $487.18.

Medpace Stock Performance

Shares of MEDP opened at $599.50 on Friday. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $626.26. The stock has a 50-day moving average price of $560.60 and a 200 day moving average price of $443.44. The company has a market capitalization of $16.89 billion, a P/E ratio of 41.92, a P/E/G ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.Medpace’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the company posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.